MarketsandMarkets Conferences, Author at Blogs & Articles

What do MNM Analysts have to say about the Immuno Oncology Market?

December 9, 2019December 9, 2019 MarketsandMarkets Conferences

Our 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress to be held on 12th-13th March 2020 in London, UK would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes, pharmaceutical, bio-pharmaceutical, and biotechnology companies to discuss the latest updates in the development of ADC’s, Bispecific Antibodies, Cellular Therapy, and Immune Checkpoint Inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case…

5th Annual Infection control, Sterilization and Decontamination congress announced with Speaker Line-up of Leading NHS Hospitals.

November 18, 2019November 18, 2019 MarketsandMarkets Conferences

MarketsandMarkets is organizing its 5th Annual Infection Control, Sterilization & Decontamination in Healthcare congress at Millennium Gloucester Hotel London Kensington on 19-20March 2020, which will focus on challenges associated with HAIs. With attendance of professionals from NHS hospitals, Research Institutes and Universities specializing in Infection Control, Decontamination and Sterilization, this two-day event will present case studies on implementation of infection prevention method and various technologies in hospitals. London, November 1 – MarketsandMarkets presents to you the 5th Annual Infection Control, Sterilization & Decontamination in Healthcare Congress to be held on…

Blood infections may be caused by bacteria in probiotics in ICU patients

November 14, 2019 MarketsandMarkets Conferences

It’s gotten normal for patients in the ICU to get probiotics, both children and adult. According to the study published in Nature Medicine, between 2009 and 2014, 1.1 % of patients suffered from bacteremia who received probiotics in the hospital’s ICU. The study also stated, the microorganisms living in probiotic formulations like yogurt can cause blood infections in few cases as indicated by a study which cautions the use of the product in the hospital’s ICU. 6 ICU cases of bacteremia was compared by the researchers with another 16 patients…

Speaker Interview with Elodie Baumfeld Andre 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress

September 10, 2019 MarketsandMarkets Conferences

Boston, September 9, 2019 – MarketsandMarkets recently interviewed Elodie Baumfeld Andre, Senior Director, Epidemiology Strategy Lead, Worldwide Medical & Safety, Pfizer regarding 2nd Annual MarketsandMarkets Real-World Data and Life Science Analytics Congress taking place on October 24 – 25, 2019 at DoubleTree by Hilton Boston-Downtown . Elodie Baumfeld Andre is the Epidemiology Strategy Lead within the Worldwide Medical & Safety group at Pfizer. In this role, Elodie’s focus is on generating Real World Evidence (RWE) to support regulatory decision-making and driving continued innovation by implementing novel clinical designs and developing operating models. She is…

Speaker Interview with Dr. Susan Astley for MarketsandMarkets Biomarker and Companion Diagnostics Conference

September 9, 2019September 9, 2019 MarketsandMarkets Conferences

London, September 3, 2019 – MarketsandMarkets recently interviewed Dr. Susan Astley, Division of Informatics, Imaging & Data Sciences, University of Manchester regarding MarketsandMarkets Biomarker and Companion Diagnostics Conference taking place on 3rd – 4th October 2019 at Radisson Blu Edwardian, Grafton, London, UK Q. What are the recent advances in Biomarker research/commercialization and current challenges that need immediate attention? A. The era of personalised medicine is with us. Biomarkers are crucial to identify those at risk of particular diseases, and those who would benefit from different preventative or therapeutic interventions….

BMS, Takeda, Celgene, Boehringer-Ingelheim & Biogen will Speak at 2nd Annual MarketsandMarkets Real-World Data & Life Science Analytics Congress

September 5, 2019September 5, 2019 MarketsandMarkets Conferences

Boston, USA, 5th September – 2nd Annual MarketsandMarkets Real-World Data & Life Science Analytics Congress will be hosting industry giants like Bristol Myers Squibb, Takeda, Genentech, Boehringer-Ingelheim, Celgene and Biogen will take place at the DoubleTree by Hilton Boston-Downtown on 25th & 26th October 2019. Presenting 20+ RWD case studies, the congress aims to discuss accelerating the adoption of Real-world Evidence, capabilities of newer technologies for evidence generation within the industry. The event agenda will focus on key aspects such as Real-World Evidence Methodologies, FDA’ strategic framework, Applications of Artificial Intelligence…

Technologies Transforming Real-World Evidence (RWE) Evidence in the Pharmaceutical Industry

September 5, 2019September 5, 2019 MarketsandMarkets Conferences

As new drugs are emerging every day, it is very important to ensure that the patients get right and effective treatment. One such step can be taken from Real World Evidence (RWE). In simple words, Real World Evidence means data and information collected outside of a clinical trial. This data can be electronic medical records, medical charts or other medical claims to assess patient outcomes. It is made sure that the patient’s identity is removed from the previous data to maintain the patient’s privacy. However, today’s real-world evidence data is…

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

August 26, 2019August 26, 2019 MarketsandMarkets Conferences

Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. The major advance has been to crack the code of immunosuppression induced by cancer, especially via checkpoint inhibitors such as antibodies to CTLA4 and PD-1/PD-L1. This has made many tumors amenable to immunotherapy. However, the generalized nature of…

Industrial Internet Consortium’s Stephen Mellor is a Speaker at the MarketsandMarkets Industry 4.0 Conference

August 13, 2019 MarketsandMarkets Conferences

Chicago – USA July 18, 2019 – Supported by IoT Council, WiMax Forum, AiSP, Industrial Internet Consortium and Global Trade Professional Alliance, MarketsandMarkets Industry 4.0 Conference: Cyber Security & IIoT will present current trends in adoption of IIoT & Cybersecurity solutions in manufacturing sector. The conference will take place on September 23-24, 2019 at Hotel Chicago Downtown, Autograph Collection, IL, inviting cross industry use cases and solutions on IIOT & Cyber Security implementations in Manufacturing. Over the two days the speakers will present real life case studies, use-cases and insights…

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

August 9, 2019August 9, 2019 MarketsandMarkets Conferences

Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and located in New-York. There, he leads the three early pipeline programs, including a novel irreversible BTK inhibitor, and anti-PD-L1 monoclonal antibody and a bispecific antibody directed against CD19 and CD47. All three assets have entered…